<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749914</url>
  </required_header>
  <id_info>
    <org_study_id>17573</org_study_id>
    <secondary_id>H8H-MC-LAIO</secondary_id>
    <nct_id>NCT04749914</nct_id>
  </id_info>
  <brief_title>A Study of Lasmiditan in Healthy Volunteers</brief_title>
  <official_title>An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to investigate the blood concentrations of dabigatran&#xD;
      etexilate and rosuvastatin when taken alone compared to when taken together with lasmiditan&#xD;
      in healthy participants. The safety and tolerability of dabigatran etexilate or rosuvastatin&#xD;
      in combination with lasmiditan will also be evaluated in healthy participants. The study has&#xD;
      two parts. Each part will last up to 17 days, not including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Actual">July 6, 2021</completion_date>
  <primary_completion_date type="Actual">July 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran to Assess P-glycoprotein (P-gp) Activity.</measure>
    <time_frame>Predose up to 72 hour postdose</time_frame>
    <description>PK: Cmax of Dabigatran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Cmax of Rosuvastatin to Assess Breast Cancer Resistance Protein (BCRP) Activity.</measure>
    <time_frame>Predose up to 72 hour postdose</time_frame>
    <description>PK: Cmax of Rosuvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞] ) of Dabigatran to Assess P-gp Activity.</measure>
    <time_frame>Predose up to 72 hour postdose</time_frame>
    <description>PK: AUC[0-∞] of Dabigatran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC[0-∞] of Rosuvastatin to Assess BCRP Activity.</measure>
    <time_frame>Predose up to 72 hour postdose</time_frame>
    <description>PK: AUC[0-∞] of Rosuvastatin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lasmiditan + Dabigatran (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single doses of dabigatran followed by combination of lasmiditan along with dabigatran etexilate administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan + Rosuvastatin (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single doses of rosuvastatin followed by combination of lasmiditan along with rosuvastatin administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Lasmiditan + Dabigatran (Part 1)</arm_group_label>
    <arm_group_label>Lasmiditan + Rosuvastatin (Part 2)</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Lasmiditan + Dabigatran (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Lasmiditan + Rosuvastatin (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 35 kilograms per meter squared (kg/m²)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have known allergies to lasmiditan, dabigatran, rosuvastatin-related compounds or any&#xD;
             components of the formulation of lasmiditan, dabigatran, rosuvastatin, or a history of&#xD;
             significant atopy&#xD;
&#xD;
          -  have an abnormal blood pressure and/or pulse rate as determined by the investigator&#xD;
&#xD;
          -  have clinically significant abnormalities on electrocardiogram (ECG) as determined by&#xD;
             investigator&#xD;
&#xD;
          -  have a history or presence of cardiovascular, respiratory, renal, gastrointestinal,&#xD;
             endocrine, hematological, or neurological disorders capable of significantly altering&#xD;
             the absorption, metabolism, or elimination of drugs; of constituting a risk when&#xD;
             taking the study interventions; or of interfering with the interpretation of data.&#xD;
             Appendectomy, splenectomy, and cholecystectomy are considered as acceptable&#xD;
&#xD;
          -  have any medical conditions, medical history, or are taking any medications that are&#xD;
             contraindicated in the dabigatran etexilate or rosuvastatin label&#xD;
&#xD;
          -  are intending to use over-the-counter or prescription medication, including dietary&#xD;
             supplements, traditional medicines, and herbal supplements, within 14 days prior to&#xD;
             dosing and until study discharge (apart from occasional acetaminophen, hormonal&#xD;
             contraception, or hormone replacement therapy)&#xD;
&#xD;
          -  currently use or show evidence of substance abuse (including alcohol abuse) or&#xD;
             dependence within the past 6 months based on history at screening&#xD;
&#xD;
          -  Part 1 Only: have known bleeding disorder including prior personal or familial history&#xD;
             of abnormal bleeding, hereditary or acquired coagulation or platelet disorder or&#xD;
             abnormal coagulation test (prothrombin time/international normalized ratio [INR] or&#xD;
             partial thromboplastin time/activated partial thromboplastin time greater than upper&#xD;
             limit of normal [ULN]) result at screening&#xD;
&#xD;
          -  Part 2 only: have c.34AA, c.421AA, or c.34GA/421CA genotypes of ABCG2 as determined&#xD;
             through genotyping&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Interaction Study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Lasmiditan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

